GALECTIN THERAPEUTIC Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (20)

Latest Posts

About This Stock More About This Stock
Galectin Therapeutics - Chart Of The Day
Article By: Jim Van Meerten
Friday, January 12, 2018 7:22 PM EDT
The Chart of the Day belongs to Galectin Therapeutics, a drug development company engaged in the development new therapies for fibrotic disease and cancer.
In this article: GALT
Read
5 Biotech Stocks To Watch As Interest In NASH Increases
Article By: Arpita Dutt
Thursday, September 22, 2016 1:45 PM EDT
The market is suddenly abuzz about nonalcoholic steatohepatitis or NASH, a common but often “silent” liver disease. Several companies are working on developing treatments for NASH – the market could be worth billions of dollars.
In this article: ICPT, CNAT, GALT, ENTA, GLMD Also: AGN
Read
Galectin Therapeutics (GALT) Misfired In 2014
Article By: Anthony Alfidi
Thursday, March 19, 2015 5:35 AM EDT
Galectin Therapeutics just cannot catch a break these days. They announced a Q4 loss this week, just a day after a law firm announced an investigation of the management team's investor relations program. It's fair to wonder what went wrong.
In this article: GALT
Read
Biotechs With Upside Possibilities Target Ebola And Liver Disease: MLV & Co.'s Vernon Bernardino
Article By: The Life Sciences Report
Wednesday, September 10, 2014 3:43 PM EDT
In this interview with The Life Sciences Report, Vernon Bernardino of MLV & Co. brings some clarity and perspective to investors who could reap windfalls from small-cap names in which shareholder value has yet to be created and realized.
In this article: NBS, GALT, BCRX, SHPG, DVAX, ICPT, ABBV, CNAT, GLMD, IMNP
Read
Wedbush Securities' Liana Moussatos On The Art And Science Of Picking Biotechs With Upside
Article By: The Life Sciences Report
Thursday, August 21, 2014 3:17 PM EDT
Liana Moussatos of Wedbush Securities doesn't wait for the catalyst to strike. She, like other successful investors, picks her targets and takes profits earlier, while less sophisticated investors wait for the press releases.
In this article: CPT, GALT, ALXN, OMER, PCRX, XOMA, UTHR
Read

PARTNER HEADLINES

Latest Tweets for $GALT

No tweets yet!